Ketogenic diet efficacy in the treatment of intractable epileptic spasms

Husam R Kayyali1, Megan Gustafson1, Tara Myers1

  • 1Division of Neurology, Department of Pediatrics, Children's Mercy Hospitals and Clinics, University of Missouri in Kansas City, Missouri.

Pediatric Neurology
|January 18, 2014
PubMed

Insights

The ketogenic diet effectively controlled epileptic spasms in infants who did not respond to traditional medications. This dietary therapy also improved quality of life and electroencephalography results in these challenging cases.

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Metabolic Therapies

Background:

  • Epileptic spasms are a severe form of epilepsy in infants.
  • Refractory cases often fail to respond to conventional antiepileptic drugs.
  • The ketogenic diet is an established therapy for drug-resistant epilepsy.

Purpose of the Study:

  • To evaluate the efficacy of the ketogenic diet for infantile epileptic spasms.
  • To assess seizure control and quality of life improvements.
  • To determine the safety and effectiveness in medication-refractory cases.

Main Methods:

  • Prospective, case-based study of infants with epileptic spasms.
  • Inclusion criteria: refractory spasms despite antiepileptic drugs and hypsarrhythmia/encephalopathy on EEG.
  • Diet efficacy assessed via clinical visits, phone communication, and EEG; quality of life via caregiver reports.

Main Results:

  • 70% of 20 infants achieved >50% seizure reduction within 3 months on the ketogenic diet.
  • Seizure reduction was maintained at 12 and 24 months.
  • Significant improvements in electroencephalography (60%) and caregiver-reported quality of life (63% within 1 month) were observed.

Conclusions:

  • The ketogenic diet is a safe and effective treatment option for infants with drug-resistant epileptic spasms.
  • It offers a viable alternative when traditional antiepileptic medications fail.
  • Positive impacts on seizure frequency, EEG, and quality of life support its use.
Abstract

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K